2026年3月18日星期三,Compass Pathways(NASDAQ:CMPS)参加了Stifel 2026虚拟中枢神经系统论坛,展示了公司的成就与挑战。该公司分享了COMP360在治疗难治性抑郁症(TRD)方面的积极研究数据,并概述了滚动新药申请(NDA)提交计划。然而,实现商业化准备仍需克服监管障碍。 要点总结 Compass Pathways计划对COMP360进行滚动NDA提交,预计 ...

Compass Pathways (NASDAQ:CMPS) executives outlined plans for a potential U.S. regulatory filing and commercial launch ...

Executives from Compass Pathways (NASDAQ:CMPS) discussed recent Phase 3 results for its COMP360 psilocybin program in treatment-resistant depression (TRD), highlighting statistically significant ...

COMPASS Pathways plc (CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, reported its financial results for the ...

Results of COMPASS Pathways’ open-label study of COMP360 psilocybin treatment, alongside SSRI antidepressants, suggest that SSRIs do not interfere with the potential therapeutic effect of COMP360 The ...

Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways ...

LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, today ...

LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the ...

COMPASS Pathways plc (NASDAQ:CMPS) is among the 7 Most Promising Psychedelic Stocks According to Hedge Funds. COMPASS ...